Beyfortus® logo

Menu

Order Beyfortus® (nirsevimab-alip) 50 mg and 100 mg Injection for Your Practice


Order Beyfortus Packaging Image

Respiratory syncytial virus (RSV) season is here

Make sure your practice is prepared

Beyfortus is available through VaccineShop,* VaxServe, and select wholesalers and distributors.† Simply create an account or log in to your existing account to order Beyfortus with immediate shipping.

Product images are representative of scale - actual size of packaging may be different.
*All direct customers on VaccineShop will receive a 2% discount and 90-day billing terms. Excludes wholesale, distributor, and public orders.
Beyfortus 50 mg and 100 mg Injection is available to purchase through wholesalers and distributors. Please call 1-800-VACCINE for more info.

A single dose for the vast majority of infants based on body weight (5O mg IM dose if <5 kg, 100 mg IM dose if ≥5 kg)1

For children undergoing cardiac surgery with cardiopulmonary bypass, an additional dose is recommended as soon as the child is stable after surgery. Please consult the Prescribing Information for complete information on dosing in this circumstance. Second season: children up to 24 months of age, regardless of body weight, who remain at increased risk for severe RSV, the recommended dosage of Beyfortus is a single 200 mg dose administered as 2 IM injections (2 x 100 mg).

Each Beyfortus pre-filled syringe is for one-time use only. Product is fully returnable upon expiration

How Beyfortus is supplied1

Beyfortus is a sterile, preservative-free injection solution that appears clear to opalescent and colorless to yellow.

Packaging and delivery type

Pre-filled syringe

Beyfortus is an intramuscular injection administered through a pre-filled syringe by a healthcare provider.

5-pack cartons

Each carton of Beyfortus contains 5 pre-filled syringes. Only 5-pack cartons are available in the United States at this time.

Dose strengths and formulation

Beyfortus packaging 50 mL

First RSV season

<5 kg weight 50 mg/0.5 mL

NDC: 49281 - 575 - 15

Beyfortus packaging 100 mL

First RSV season

≥5 kg weight 100 mg/1 mL

NDC: 49281-574-15

Beyfortus packaging 100 mL

Second RSV season

Any weight 2 x 100 mg/1 mL

NDC: 49281-574-15

Product images are representative of scale - actual size of packaging may be different.

shield

Administration Details for Beyfortus

Beyfortus mAb image

Codes and Reimbursement Information

Important Safety Information

Contraindication
Beyfortus is contraindicated in infants and children with a history of serious hypersensitivity reactions, including anaphylaxis, to nirsevimab-alip or to any of the excipients.

Warnings and Precautions
  • Hypersensitivity Reactions Including Anaphylaxis: Serious hypersensitivity reactions have been reported following Beyfortus administration. These reactions included urticaria, dyspnea, cyanosis, and/or hypotonia. Anaphylaxis has been observed with human immunoglobulin G1 (IgG1) monoclonal antibodies. If signs and symptoms of anaphylaxis or other clinically significant hypersensitivity reactions occur, initiate appropriate treatment.

  • Use in Individuals with Clinically Significant Bleeding Disorders: As with other IM injections, Beyfortus should be given with caution to infants and children with thrombocytopenia, any coagulation disorder or to individuals on anticoagulation therapy.

Most common adverse reactions with Beyfortus were rash (0.9%) and injection site reactions (0.3%).

Indication

Beyfortus is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in:

  • Neonates and infants born during or entering their first RSV season.
  • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.

Important Safety Information

Indication

Reference: 1. Beyfortus (nirsevimab). Prescribing Information. Sanofi.

MAT-US-2310578-v8.0-10/2024